Tocotrienol and bevacizumab in metastatic colorectal cancer. A randomized phase II marker trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517075-21-00

Acronym

Toco-CoR

Enrollment

Registered

2024-09-27

Start date

2020-06-26

Completion date

Unknown

Last updated

2024-09-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Colorectal cancer

Brief summary

The rate of progression free patients at six months.

Interventions

DRUGCAPECITABINE

DRUGFLUOROURACIL

DRUGCALCIUM FOLINATE

DRUGBEVACIZUMAB

DRUGPLACEBO

DRUGOXALIPLATIN

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The rate of progression free patients at six months.	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026